FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048755251> ?p ?o ?g. }

• W3048755251 endingPage "e2013211" @default.
• W3048755251 startingPage "e2013211" @default.
• W3048755251 abstract "<h3>Importance</h3> A single subanesthetic dose of ketamine produces an antidepressant response in patients with major depressive disorder (MDD) within hours, but the mechanism of antidepressant effect is uncertain. <h3>Objective</h3> To evaluate whether ketamine dose and brain glutamate and glutamine (Glx) and γ-aminobutyric acid (GABA) level responses to ketamine are related to antidepressant benefit and adverse effects. <h3>Design, Setting, and Participants</h3> This randomized, parallel-group, triple-masked clinical trial included 38 physically healthy, psychotropic medication–free adult outpatients who were in a major depressive episode of MDD but not actively suicidal. The trial was conducted at Columbia University Medical Center. Data were collected from February 2012 to May 2015. Data analysis was conducted from January to March 2020. <h3>Intervention</h3> Participants received 1 dose of placebo or ketamine (0.1, 0.2, 0.3, 0.4, or 0.5 mg/kg) intravenously during 40 minutes of a proton magnetic resonance spectroscopy scan that measured ventro-medial prefrontal cortex Glx and GABA levels in 13-minute data frames. <h3>Main Outcomes and Measures</h3> Clinical improvement was measured using a 22-item version of the Hamilton Depression Rating Scale (HDRS-22) 24 hours after ketamine was administered. Ketamine and metabolite blood levels were measured after the scan. <h3>Results</h3> A total of 38 individuals participated in the study, with a mean (SD) age of 38.6 (11.2) years, 23 (60.5%) women, and 25 (65.8%) White patients. Improvement in HDRS-22 score at 24 hours correlated positively with ketamine dose (<i>t</i>₃₆ = 2.81;<i>P</i> = .008; slope estimate, 19.80 [95% CI, 5.49 to 34.11]) and blood level (<i>t</i>₃₆ = 2.25;<i>P</i> = .03; slope estimate, 0.070 [95% CI, 0.007 to 0.133]). The lower the Glx response, the better the antidepressant response (<i>t</i>₃₃ = −2.400;<i>P</i> = .02; slope estimate, −9.85 [95% CI, −18.2 to −1.50]). Although GABA levels correlated with Glx (<i>t</i>₃₃ = 8.117;<i>P</i> < .001; slope estimate, 0.510 [95% CI, 0.382 to 0.638]), GABA response did not correlate with antidepressant effect. When both ketamine dose and Glx response were included in a mediation analysis model, ketamine dose was no longer associated with antidepressant effect, indicating that Glx response mediated the relationship. Adverse effects were related to blood levels in men only (<i>t</i>₅ = 2.606;<i>P</i> = .048; estimated slope, 0.093 [95% CI, 0.001 to 0.186]), but Glx and GABA response were not related to adverse effects. <h3>Conclusions and Relevance</h3> In this study, intravenous ketamine dose and blood levels correlated positively with antidepressant response. The Glx response correlated inversely with ketamine dose and with antidepressant effect. Future studies are needed to determine whether the relationship between Glx level and antidepressant effect is due to glutamate or glutamine. <h3>Trial Registration</h3> ClinicalTrials.gov Identifier:NCT01558063" @default.
• W3048755251 created "2020-08-18" @default.
• W3048755251 creator A5002562154 @default.
• W3048755251 creator A5008012136 @default.
• W3048755251 creator A5011278823 @default.
• W3048755251 creator A5022050377 @default.
• W3048755251 creator A5025902845 @default.
• W3048755251 creator A5027263611 @default.
• W3048755251 creator A5030014983 @default.
• W3048755251 creator A5058205666 @default.
• W3048755251 creator A5061929421 @default.
• W3048755251 creator A5063209847 @default.
• W3048755251 creator A5063655069 @default.
• W3048755251 creator A5078379884 @default.
• W3048755251 creator A5081965846 @default.
• W3048755251 creator A5090507160 @default.
• W3048755251 date "2020-08-12" @default.
• W3048755251 modified "2023-09-26" @default.
• W3048755251 title "Assessment of Relationship of Ketamine Dose With Magnetic Resonance Spectroscopy of Glx and GABA Responses in Adults With Major Depression" @default.
• W3048755251 cites W1638218062 @default.
• W3048755251 cites W1748696538 @default.
• W3048755251 cites W1846441878 @default.
• W3048755251 cites W1909229392 @default.
• W3048755251 cites W1914381346 @default.
• W3048755251 cites W1948877773 @default.
• W3048755251 cites W1964466640 @default.
• W3048755251 cites W1966424565 @default.
• W3048755251 cites W1971440513 @default.
• W3048755251 cites W1987239750 @default.
• W3048755251 cites W1992333267 @default.
• W3048755251 cites W1993300625 @default.
• W3048755251 cites W1997232706 @default.
• W3048755251 cites W2003982930 @default.
• W3048755251 cites W2013392366 @default.
• W3048755251 cites W2015155779 @default.
• W3048755251 cites W2015569119 @default.
• W3048755251 cites W2018114814 @default.
• W3048755251 cites W2023081218 @default.
• W3048755251 cites W2027744361 @default.
• W3048755251 cites W2032739515 @default.
• W3048755251 cites W2039056175 @default.
• W3048755251 cites W2047801483 @default.
• W3048755251 cites W2049785176 @default.
• W3048755251 cites W2062230026 @default.
• W3048755251 cites W2068026567 @default.
• W3048755251 cites W2076682630 @default.
• W3048755251 cites W2080742815 @default.
• W3048755251 cites W2083651237 @default.
• W3048755251 cites W2087002084 @default.
• W3048755251 cites W2089351762 @default.
• W3048755251 cites W2103218986 @default.
• W3048755251 cites W2103220129 @default.
• W3048755251 cites W2103255996 @default.
• W3048755251 cites W2103903531 @default.
• W3048755251 cites W2104460069 @default.
• W3048755251 cites W2107849028 @default.
• W3048755251 cites W2109334244 @default.
• W3048755251 cites W2111728433 @default.
• W3048755251 cites W2118815581 @default.
• W3048755251 cites W2123476505 @default.
• W3048755251 cites W2124136543 @default.
• W3048755251 cites W2124203952 @default.
• W3048755251 cites W2128918664 @default.
• W3048755251 cites W2148880706 @default.
• W3048755251 cites W2153739619 @default.
• W3048755251 cites W2197394318 @default.
• W3048755251 cites W2330587564 @default.
• W3048755251 cites W2346390990 @default.
• W3048755251 cites W2377185146 @default.
• W3048755251 cites W2417348168 @default.
• W3048755251 cites W2528777034 @default.
• W3048755251 cites W254805310 @default.
• W3048755251 cites W2594365286 @default.
• W3048755251 cites W2607180956 @default.
• W3048755251 cites W2608506675 @default.
• W3048755251 cites W2618399463 @default.
• W3048755251 cites W2631673659 @default.
• W3048755251 cites W2737966001 @default.
• W3048755251 cites W2752781070 @default.
• W3048755251 cites W2765759410 @default.
• W3048755251 cites W2768515234 @default.
• W3048755251 cites W2771797851 @default.
• W3048755251 cites W2811304329 @default.
• W3048755251 cites W2895197076 @default.
• W3048755251 cites W2935995671 @default.
• W3048755251 cites W2970684805 @default.
• W3048755251 cites W4239780674 @default.
• W3048755251 cites W4244531155 @default.
• W3048755251 cites W4244794934 @default.
• W3048755251 cites W4256059665 @default.
• W3048755251 cites W4292811746 @default.
• W3048755251 cites W67980595 @default.
• W3048755251 doi "https://doi.org/10.1001/jamanetworkopen.2020.13211" @default.
• W3048755251 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7424409" @default.
• W3048755251 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32785636" @default.
• W3048755251 hasPublicationYear "2020" @default.
• W3048755251 type Work @default.
• W3048755251 sameAs 3048755251 @default.

• next